Scarica l'app Stockscreener
0.2314
4.23%
0.0094
Dopo l'orario di chiusura:
.22
-0.0114
-4.93%
Precedente Chiudi:
$0.222
Aprire:
$0.222
Volume 24 ore:
290.07K
Relative Volume:
0.47
Capitalizzazione di mercato:
$8.70M
Reddito:
-
Utile/perdita netta:
$-51.06M
Rapporto P/E:
-0.1677
EPS:
-1.38
Flusso di cassa netto:
$-40.03M
1 W Prestazione:
+5.23%
1M Prestazione:
+8.33%
6M Prestazione:
-77.31%
1 anno Prestazione:
-77.75%
Intervallo 1D:
$0.2118
$0.235
Intervallo di 1 settimana:
$0.2118
$0.235
Portata 52W:
$0.202
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Nome
Viracta Therapeutics Inc
Settore
Industria
Telefono
858-400-8470
Indirizzo
2533 S COAST HWY 101, CARDIFF
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-03 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Iniziato | SVB Leerink | Outperform |
| 2021-03-25 | Iniziato | Evercore ISI | Outperform |
Viracta Therapeutics Inc Borsa (VIRX) Ultime notizie
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com Canada
The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle
Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News
Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News
Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News
Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News
Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Perhaps timely catching Viracta Therapeutics Inc (VIRX) would be a good idea - SETE News
Biopharma Layoff Tracker 2024: Lykos, Galera, Grail and More Cut Staff - BioSpace
Examining Viracta Therapeutics Inc (VIRX) stock is warranted - US Post News
Viracta Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Stock Surge: Viracta Therapeutics Inc (VIRX) Closes at 0.31, Marking a -11.76 Increase/Decrease - The Dwinnex
Viracta Therapeutics (NASDAQ:VIRX) PT Lowered to $4.00 - Defense World
Viracta Therapeutics (NASDAQ:VIRX) Downgraded by SVB Leerink to “Market Perform” - Defense World
What is Viracta Therapeutics Inc (VIRX) Stock Return on Shareholders’ Capital? - SETE News
Viracta Therapeutics stock PT lowered by RBC amid pipeline strategy shift - Investing.com Canada
Viracta reports progress in PTCL treatment trial By Investing.com - Investing.com Australia
Sunesis: Q2 Earnings Snapshot - San Antonio Express-News
Sunesis: Q2 Earnings Snapshot - Thehour.com
Viracta reports progress in PTCL treatment trial - Investing.com
A Closer Look at Viracta Therapeutics Inc (VIRX) Stock Gains - The InvestChronicle
Sunesis: Q2 Earnings Snapshot - The Washington Post
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024 - MSN
VIRX stock touches 52-week low at $0.38 amid market challenges - Investing.com Canada
New CEOs and positive earnings have these stocks moving - RagingBull
Sunesis: Q2 Earnings Snapshot - San Francisco Chronicle
Viracta Therapeutics Announces Positive Data from the Phase - GlobeNewswire
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday? - Benzinga
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today? - InvestorPlace
Viracta stock jumps after corporate update (NASDAQ:VIRX) - Seeking Alpha
VIRXViracta Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - StockTitan
Are Viracta Therapeutics Inc’shares a good deal? - US Post News
Daily Market Movement: Viracta Therapeutics Inc (VIRX) Sees a 0.59 Increase, Closing at 0.44 - The Dwinnex
VIRX stock touches 52-week low at $0.43 amid market challenges - Investing.com
Viracta Therapeutics announces workforce reduction - Investing.com
Short Interest in Viracta Therapeutics, Inc. (NASDAQ:VIRX) Grows By 35.2% - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up to $28.09 - Defense World
Viracta Therapeutics (NASDAQ:VIRX) Trading Down 1.1% - Defense World
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement - Quantisnow
Viracta Therapeutics (NASDAQ:VIRX) Stock Price Down 1.8% - Defense World
Viracta Therapeutics Inc Azioni (VIRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):